JMT108 is named as an intervention in 3 current clinical trials in our China and USA registers. 3 are recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is Shanghai JMT-Bio Inc (2). The most-studied condition is Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors
NCT06877650 · ClinicalTrials.gov ↗ · Advanced Malignant Tumors
|
Phase 1/2 | Recruiting | Shanghai JMT-Bio Inc. | China |
|
Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors
NCT07280832 · ClinicalTrials.gov ↗ · Unresectable Locally Advanced or Metastatic Melanoma, Unresectable Locally Advanced or Metastatic Urinary Tract Tumors
|
Phase 1/2 | Recruiting | Shanghai JMT-Bio Inc. | China |
|
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
NCT07317505 · ClinicalTrials.gov ↗ · Cancer, Cancer (Solid Tumors)
|
Phase 1 | Recruiting | Conjupro Biotherapeutics, Inc. | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Shanghai JMT-Bio Inc. | 2 |
| Conjupro Biotherapeutics, Inc. | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
| Clinical trials in USA | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China and USA registers name JMT108 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 3 trials are recruiting: 2 with sites in China and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Shanghai JMT-Bio Inc (2) and Conjupro Biotherapeutics, Inc (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how JMT108 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how JMT108 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists JMT108 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.